EBV DNA guided immunotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests if an immunotherapy drug (adebrelimab) can help people with advanced nasopharyngeal cancer whose Epstein-Barr virus (EBV) DNA levels stay high or stable after initial chemotherapy. It aims to see if this personalized approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing, confirmed by biopsy.
- Your cancer is stage II or III (but not T3N0-1).
- You have had 3 cycles of chemotherapy (gemcitabine, cisplatin) and your EBV DNA is still high or your disease hasn't worsened.
- You are in generally good health with adequate blood cell counts and normal liver, kidney, and heart function.
- You are willing to give informed consent and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination therapy that first wakes up the Epstein-Barr virus (EBV) in cancer cells and then uses an immune-boosting drug (PD-1 antibody) to help your body attack them. It is for people whose nasopharyngeal cancer has come back or spread to other parts of the body.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.